Evidence mapPaperPMID 39445155Full record

ReviewInternational journal of nanomedicine2024

The Advances in the Development of Epigenetic Modifications Therapeutic Drugs Delivery Systems.

Tingyi Li, Yanwei Chen, Shuai Li

Abstract readReview
In one paragraph

Review in International journal of nanomedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Tingyi LiDepartment of Pharmacy, The First Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China.
Yanwei ChenDepartment of Pharmacy, The First Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China.
Shuai LiDepartment of Pharmacy, The First Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China.ORCID 0000-0002-3492-7176

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epigenetic dysregulation can significantly trigger the onset and progression of various diseases, epigenetic therapy is a new treatment strategy by changing DNA methylation, histone modification, N6-methyladenosine, chromatin modification and other epigenetic modifications to regulate gene expression levels for therapeutic purposes. However, small-molecule epigenetic drugs face challenges in disease treatment, such as lack of selectivity, limited therapeutic efficacy, and insufficient safety. Nanomedicine delivery systems offer significant advantages in addressing these issues by enhancing drug targeting, improving bioavailability, and reducing nonspecific distribution. This help minimize side effects while increasing both therapeutic effectiveness and safety of epigenetic drugs. In this review, we focus on the mechanism and role of epigenetic regulatory factors in diseases, as well as the challenges faced by small molecule inhibitors in treatment strategies, especially the research advancements in epigenetic drug delivery systems, review and discuss the therapeutic potential and challenges of using nanotechnology to develop epigenetic drug delivery systems.

Indexed as

Drug Delivery SystemsEpigenesis, GeneticNanomedicineAnimalsDNA MethylationHumansNanoparticlesDNA methylationepigenetic therapyhistone modificationN6-methyladenosinenanomedicine delivery systemsnanotechnology

Identifiers

PMID39445155
PMCPMC11498046

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.